Magnesium sulphate

Generic name
Magnesium sulphate
Brand name
ATC Code
A12CC02
Compare …

Magnesium sulphate

Dosages
Side effects in children
Warnings & precautions in children
Contra-indications in children

Interactions
PK
Renal impairment
References

Pharmacokinetics in children

No pharmacokinetic data known for children.

dose recommendation of formulary compared to licensed use (on-label versus off-label)

No information is present at this moment.

Available formulations

No information is present at this moment.

Dosages

Go to:

Constipation
  • Oral
    • 2 years up to 6 years
      • 2.5 - 5 g/day in 2 - 4 doses.
    • 6 years up to 12 years
      • 5 - 10 g/day in 2 - 4 doses.
    • ≥ 12 years
      • 10 - 30 g/day in 2 - 4 doses.
Asthmatic status
  • Intravenous
    • 1 month up to 18 years
      • 40 mg/kg/dose in 10-15 min. Max single dose: 2 g/dose.
  • Inhalation
    • 2 years up to 6 years
      • 150 mg/dose, as required, max. 3 doses. within the first hour of treatment..
        • Inhaled use is not recommended for other children.
Hypomagnesaemia, ventricular arrhythmias
  • Intravenous
    • 1 month up to 18 years
      • Initial dose: 25 - 50 mg/kg/dose, bolus in 3 min and repeat if necessary. Max: 2 g/dose.
      • Maintenance dose: 3 - 20 mg/kg/hour, continuous infusion.
        • 15 mg magnesiumsulfaat (7-water) is equivalent to 0,06 mmol Magnesium;
        • 2 g magnesiumsulfaat (7-water) is equivalent to 8 mmol Magnesium.
        • 3 - 20 mg magnesiumsulfaat (7-water) is equivalent to 0,01 - 0,08 mmol Magnesium.

          Only limited clinical research has been carried out into the use of magnesium sulphate in children with ventricular tachycardia.
Convulsion due to acute nephritis
  • Intramuscular
    • 1 month up to 18 years
      • 15% solution (150 mg/ml): 20 - 40 mg/kg/dose, once only.

Renal impaiment in children > 3 months

No information available on dose adjustment in renal impairment.

The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here

Side effects in children

Diarrhoea, hypotension, muscular weakness, drowsiness. In overdoses or excessively rapid administration: flushing, depression of the central nervous system, respiratory depression and ECG abnormalities.

The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here

Contra-indications

No information available on specific contra indications in children.

The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here

Warnings & precautions in children

1 g of magnesium sulphate.7H2O contains 4.06 mmol magnesium. Intravenous administration should be done slowly, guided by regular monitoring of the clinical picture (respiration, blood pressure, patellar reflex, urinary excretion) and the magnesium concentrations. Excessively rapid administration can make the patient feel very warm and can ultimately lead to respiratory or cardiac arrest.

Interactions

The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here

OTHER MINERAL SUPPLEMENTS

This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.

Sodium
A12CA01
Zinc
A12CB01
Magnesium
A12CC05
A12CC01
A12CC04
A12CC03
Selenium
A12CE02
Other mineral products
A12CX
MAGNESIUM
A12CC05
A12CC01
A12CC04
A12CC03
OTHER MINERAL PRODUCTS
A12CX

References

  1. Rademaker C.M.A. et al, Geneesmiddelen-Formularium voor Kinderen, 2007
  2. Pharmachemie BV, RVG 52332, www.cbg-meb.nl, 8 feb 1993, http://db.cbg-meb.nl/IB-teksten/h51948-h52332.pdf (geraadpleegd 07 april 2010)
  3. Mohammed S et al, Intravenous and nebulised magnesium sulphate for acute asthma: systematic review and meta-analysis., Emerg Med J, 2007, Dec;24(12), 823-30
  4. Rowe BH, Magnesium sulfate for treating exacerbations of acute asthma in the emergency department, Cochrane Database Syst Rev, 2000, (2), CD001490
  5. Cheuk DK et al, A meta-analysis on intravenous magnesium sulphate for treating acute asthma, Arch Dis Child, 2005, Jan;90(1), 74-7
  6. Devi PR et al, Intravenous magnesium sulfate in acute severe asthma not responding to conventional therapy, Indian Pediatr, 1197, May;34(5), 389-97
  7. Scarfone RJ, A randomized trial of magnesium in the emergency department treatment of children with asthma, Ann Emerg Med, 2000, Dec;36(6):, 572-8
  8. Gürkan F et al, Intravenous magnesium sulphate in the management of moderate to severe acute asthmatic children nonresponding to conventional therapy, Eur J Emerg Med, 1999, Sep;6(3), 201-5
  9. Ciarallo L, Higher-dose intravenous magnesium therapy for children with moderate to severe acute asthma, Arch Pediatr Adolesc Med, 2000, Oct;154(10), 979-83
  10. Ciarallo L et al, Intravenous magnesium therapy for moderate to severe pediatric asthma: results of a randomized, placebo-controlled trial, J Pediatr, 1996, Dec;129(6), 809-14
  11. NVK, Richtlijn Astma bij Kinderen, 2013
  12. Turner, NM, Leroy, P, Advanced Paediatric Life Support, de Nederlandse editie, Bohn, Stafleu van Loghum, 2017, 5e druk
  13. Global Initiative for Asthma (GINA), Global strategy for Asthma management and prevention, https://ginasthma.org/gina-reports/, 2020, 159-60

Changes

Therapeutic Drug Monitoring


Overdose